Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
December 18, 2025
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
May 5, 2022
Related Post
-
-
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
December 17, 2025
-
Iterum Therapeutics Provides Business Update
December 17, 2025
-
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
December 12, 2025